Evidence map›Paper›PMID 33498831›Full record

ArticleMolecules (Basel, Switzerland)2021

Basic Pharmacological Characterization of EV-34, a New H

Alexandra Gyöngyösi, Vivien Verner, Ilona Bereczki, Attila Kiss-Szikszai, Rita Zilinyi, Árpád Tósaki, István Bak, Anikó Borbás, Pál Herczegh, István Lekli

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Synthesis, HScientific reports · 2025
    Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Alexandra GyöngyösiDepartment of Pharmacology, Faculty of Pharmacy, University of Debrecen, 4032 Debrecen, Hungary.
Vivien VernerDepartment of Pharmacology, Faculty of Pharmacy, University of Debrecen, 4032 Debrecen, Hungary.
Ilona BereczkiDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Debrecen, 4032 Debrecen, Hungary.ORCID 0000-0003-4601-7257
Attila Kiss-SzikszaiDepartment of Organic Chemistry, Faculty of Science and Technology, University of Debrecen, 4032 Debrecen, Hungary.ORCID 0000-0003-3601-5143
Rita ZilinyiDepartment of Pharmacology, Faculty of Pharmacy, University of Debrecen, 4032 Debrecen, Hungary.
Árpád TósakiDepartment of Pharmacology, Faculty of Pharmacy, University of Debrecen, 4032 Debrecen, Hungary.
István BakDepartment of Bioanalytical Chemistry, Faculty of Pharmacy, University of Debrecen, 4032 Debrecen, Hungary.
Anikó BorbásDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Debrecen, 4032 Debrecen, Hungary.ORCID 0000-0001-8462-4547
Pál HerczeghDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Debrecen, 4032 Debrecen, Hungary.
István LekliDepartment of Pharmacology, Faculty of Pharmacy, University of Debrecen, 4032 Debrecen, Hungary.
University of Debrecen · HU

Funding

European Union and the European Social Fund EFOP-3.6.1-16-2016-00022European Union and the European Social Fund GINOP-2.3.2-15-2016-00043Innovációs és Technológiai Minisztérium: Tématerületi Kiválósági Program TKP2020-IKA-04Nemzeti Kutatási Fejlesztési és Innovációs Hivatal NKFIH-1150-6/2019Nemzeti Kutatási Fejlesztési és Innovációs Hivatal NKFIH-K-124719Nemzeti Kutatási Fejlesztési és Innovációs Hivatal NKFIH-K-132870
6 · The paper itself

Abstract

backgroundCardioprotective effects of H

methodsFollowing the synthesis of EV-34, a new H

resultsThe results revealed that the molecule is stable under oxidative condition of Fenton reaction. However, EV-34 undergoes biodegradation in rat serum and liver lysates. In cell culture medium H

conclusionThe results indicate that EV-34 is a safe H

Indexed as

AnimalsAnti-Inflammatory AgentsAnti-Inflammatory Agents, Non-SteroidalCell LineCyclooxygenase InhibitorsHydrogen SulfideIbuprofenInflammationMaleOxidative StressProstaglandin-Endoperoxide SynthasesRatsRats, Sprague-DawleyAnti-Inflammatory AgentsAnti-Inflammatory Agents, Non-SteroidalCyclooxygenase InhibitorsHydrogen SulfideIbuprofenProstaglandin-Endoperoxide Synthasesanti-inflammatory propertygasotransmitterH2S-releasing-ibuprofenhydrogen-sulfidethiolacetic acid

Identifiers

PMID33498831
PMCPMC7865354
OpenAlexW3122183116

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.